|
|
|
|
|
|
|
|
|
|
|
02.04.26 - 14:03
|
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium (GlobeNewswire EN)
|
|
|
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in one-on-one investor meetings at the upcoming Raymond James Biotech Innovation Symposium in New York City, on April 14th, 2026....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.11.25 - 22:06
|
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update (Business Wire)
|
|
|
On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026
Results from healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, expected in H1 2026
Cash runway sufficient to fund operations into Q4 2026HOUSTON--(BUSINESS WIRE)--#IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the third quarter ended September 30, 2025, and provided a business update.
Third Quarter 2025 and Recent Highlights:
Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipated in the first half of 2026.
Announced that the IND for its next-generation STAT3 inhibitor, TTI-109, is in effect and that a healthy volunteer study has been initiated, results of which are anticipated in the first half ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
